Metabolic-Fit / 100
NuuVim review
A rare needle-free option at true price parity — $79/mo semaglutide or $133/mo tirzepatide, injectable or oral, same price — though NuuVim frames it as a new-patient rate with an unpublished refill tier, and its 50-state coverage claim couldn't be confirmed on its own live site this pass.
- HSA / FSA-eligible
- Editor-vetted
- No insurance needed
Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure in this piece is cited inline to its primary source — the trial or the FDA label — so you can open it and check us. This is background reading, not medical advice.
NuuVim at a glance
- Semaglutide
- $79/mo | New GLP-1 Users
- Tirzepatide
- $133/mo | New GLP-1 Users
- Coverage
- Not verified by observation
- Brand-name
- Yes
How we scored NuuVim
Every factor comes from NuuVim's own published pricing, disclosures and oversight, and the six combine into the 37/100 Metabolic-Fit Score by the same weighted six-factor framework we apply to every provider — never nudged by whether a provider pays us.
No postpartum or breastfeeding framing — a generic weight program.
Thin on the hormonal picture that drives many mothers' weight.
Oversight and lab support fall short of the top of this roster — the review below says exactly where.
Cost is unpredictable or sits at the premium end.
Support is thin once the prescription ships.
Exit terms are the weak point: lock-in, notice periods, or a cancellation you have to chase.
How we verified this review
- Last verified
- August 2026
- Confidence
- medium
- Primary source
- www.nuuvim.com
$79 for semaglutide and $133 for tirzepatide on the new-patient tier — a standing tier rather than a countdown promotion, though the ongoing refill price is not published anywhere. Oral access at the same price as the injectable is genuinely uncommon here. NuuVim states plainly that it does not manufacture compounded medications.
What to expect when you sign up
We walked NuuVim's public signup funnel (August 2026) — a first-hand look at the flow. We don't create accounts, enter medical data, or complete checkout, so this is what any visitor sees, not a patient outcome.
- 1The signup call to action leaves nuuvim.com for start.nuuvim.com, a separate host
What we noticed
- The intake runs on Bask Health rather than on the provider's own software
- A monthly price is visible on the public homepage before any intake — you do not have to hand over information to see a number
- Intake is hosted on start.nuuvim.com, so the company you fill the form in with is not the domain you started on
Pricing
Prices re-verified
| Medication | Monthly | Plan |
|---|---|---|
| Compounded semaglutide | $79 | Injectable or oral — new-patient rateInjectable and oral semaglutide are priced the same. This is a standing new-patient tier, not a countdown-timer promo — but NuuVim itself frames it as a 'new GLP-1 users' rate, implying a different, unpublished refill-tier number likely applies after the first fill. |
| Compounded tirzepatide | $133 | Injectable or oral — new-patient rateInjectable and oral tirzepatide are priced the same. Same new-patient framing and refill-tier caveat as semaglutide. |
| Brand semaglutide | $1498 | Ozempic (brand-name)Priced far above LillyDirect/NovoCare-style manufacturer self-pay channels. |
| Brand tirzepatide | $1892 | Zepbound (brand-name)Priced far above manufacturer self-pay channels. |
Swipe the table to see plan details →
Many HSA and FSA plans cover GLP-1 telehealth — check yours. These figures are what NuuVim's own site disclosed at last review; this market re-prices often, so confirm the current number at the source.
What we like
- Oral and injectable priced identically for both semaglutide and tirzepatide — genuinely uncommon
- LegitScript-certified and HIPAA-compliant
- Explicitly discloses it does not manufacture its own compounded medications
- Brand-name Ozempic and Zepbound available as a fallback option
The caveats
- The $79/$133 rate is explicitly a new-patient tier; the ongoing refill price isn't published
- 50-state coverage is the affiliate directory claim, not something this review could confirm on NuuVim's own live site
- Brand-name options are priced far above manufacturer-direct self-pay channels
- No postpartum, breastfeeding or PCOS-specific guidance found
NuuVim for mothers: our verdict
A rare needle-free option at true price parity — $79/mo semaglutide or $133/mo tirzepatide, injectable or oral, same price — though NuuVim frames it as a new-patient rate with an unpublished refill tier, and its 50-state coverage claim couldn't be confirmed on its own live site this pass. It runs about $79/month — toward the affordable end of what we track.
We weigh NuuVim the way mothers actually have to: not just the monthly cost, but postpartum and breastfeeding timing and PCOS and insulin resistance — the parts a general weight-loss roundup leaves out.
What NuuVim costs, in full
- Compounded semaglutide — Injectable or oral — new-patient rate: $79/mo
- Compounded tirzepatide — Injectable or oral — new-patient rate: $133/mo
- Brand-name semaglutide — Ozempic (brand-name): $1498/mo
- Brand-name tirzepatide — Zepbound (brand-name): $1892/mo
That sits below the roughly $179 median ongoing price across the providers we track for mothers — a real cost advantage.
On that last point NuuVim is no help: it doesn't break down what the monthly figure covers — whether the provider visit, shipping and any lab work are inside it or billed separately. Ask before you pay, because that answer is what decides whether a mid-range price is actually mid-range.
The medications NuuVim prescribes
NuuVim prescribes semaglutide and tirzepatide — the two with the largest published weight-loss effects, and carrying both on one account matters when insulin resistance, common with PCOS and after gestational diabetes, makes tirzepatide the better-suited option. Brand pens are available here alongside the compounded versions, and the on-label products come with the manufacturer's own pregnancy and lactation labeling — easier to hand to an OB.
A needle-free oral or sublingual option is on the menu, which draws in mothers who've been avoiding injections — just set expectations: oral and buccal delivery of these peptides is far less studied than the injectable versions the trials used.
Where NuuVim fits — and where it doesn't — for mothers
A good fit if…
- the monthly cost is a real barrier and you want a low, predictable number.
- switching between semaglutide and tirzepatide may become necessary as your body and your hormones change.
Look elsewhere if…
- you'd rather a prescriber talk through timing around postpartum and breastfeeding timing — that is the ground our #1 pick, CoreAge Rx, is built on.
Oversight, safety, and what we could verify
Our confidence is moderate — the core facts check out, but some details (per-state availability, program mechanics) aren't fully public. As with any compounded GLP-1, the most useful thing mothers can do is confirm which licensed pharmacy fills the prescription and what's in the formulation — we explain how we weigh oversight in our scoring methodology.
A standing caveat for mothers: GLP-1 medications aren't established as safe during pregnancy or breastfeeding, and every label advises against use. Nothing here changes that — plan the timing with your own clinician.
The bottom line
NuuVim is a genuine value play — weigh it on postpartum and breastfeeding timing and PCOS and insulin resistance against the alternatives below. For most mothers, CoreAge Rx remains the stronger all-round fit — see why it tops our ranking.
The bottom line for mothers
Best for: Mothers who want oral GLP-1 at the same price as the injection and are willing to confirm the refill-tier price before their first fill runs out.
Alternatives to NuuVim
Providers we have a referral relationship with, ordered by their Metabolic-Fit Score — highest first. This module leaves out the provider whose page you are reading, so on CoreAge Rx's own review our #1 pick is the one name you will not find here. These are not the whole roster: see the full ranking for every provider we cover, paid or not.
- Visit CoreAge Rx92
Metabolic-Fit / 100
CoreAge RxOur #1 pickOne flat price, both molecules on a single chart, and a prescriber who reads your history before writing — the most predictable place for a mother to start and, just as important, to pause.
- Visit Gala Health84
Metabolic-Fit / 100
A flat $179 for either molecule with a genuinely gentle microdosing tier — a reasonable, all-doses-included option if you can live with a yearly plan and a pharmacy it doesn't name.
- Visit Enhance MD81
Metabolic-Fit / 100
One of the more oversight-forward compounded programs here — lab work and a live provider visit bundled into every plan, with a gentle microdosing tier — the catch is that the low '$212' headline you'll see quoted is the 12-month prepay rate, not the $249 you'd pay month to month.
Keep comparing NuuVim
Head-to-head & alternatives
NuuVim, answered
- How much does NuuVim cost as a new patient?
- $79/mo for semaglutide and $133/mo for tirzepatide, injectable or oral at the same price — a genuinely rare needle-free option at price parity. NuuVim frames this as a 'New GLP-1 Users' rate, which suggests an unpublished, likely higher refill-tier price applies later; ask before your first fill runs out.
- Does NuuVim serve all 50 states?
- That's the affiliate directory claim, but this review could not verify it directly on NuuVim's own live site as of August 5, 2026 — treat it as not confirmed by observation, and check with NuuVim directly.
- Can I get brand-name Ozempic or Zepbound through NuuVim?
- Yes, both are listed — Ozempic at $1,498/mo and Zepbound at $1,892/mo — but both sit well above what you'd pay through LillyDirect or NovoCare's own manufacturer self-pay channels.
Pricing, states and verification reflect NuuVim's public disclosures at last review; the Metabolic-Fit Score is our editorial judgment per the published methodology. This is background reading, not medical advice — GLP-1 medications are not established as safe in pregnancy or breastfeeding. See our medical disclaimer and how we're funded.